{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:58:01Z","timestamp":1772197081271,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82200113"],"award-info":[{"award-number":["No.82200113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82170105"],"award-info":[{"award-number":["No.82170105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82300123"],"award-info":[{"award-number":["No.82300123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82370095"],"award-info":[{"award-number":["No.82370095"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11596-025-00158-5","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:26:59Z","timestamp":1768915619000},"page":"197-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Huaier Aqueous Extract Combined with Gefitinib Promotes ACSL4-Dependent Ferroptosis and Overcomes Gefitinib Resistance in Non-Small Cell Lung Cancer"],"prefix":"10.1007","volume":"46","author":[{"given":"Yi-heng","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-qian","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3120-3017","authenticated-orcid":false,"given":"Qiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"1","key":"158_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin."},{"issue":"9","key":"158_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624\u2013639.","journal-title":"Nat Rev Clin Oncol."},{"issue":"10066","key":"158_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299\u2013311.","journal-title":"Lancet."},{"key":"158_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini E, Maroni G, Del Re M, et al. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253\u2013275.","journal-title":"Semin Cancer Biol."},{"issue":"4","key":"158_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro A, J\u00e4nne PA, Mok T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377\u2013391.","journal-title":"Nat Cancer."},{"issue":"10454","key":"158_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404(10454):803\u2013822.","journal-title":"Lancet."},{"key":"158_CR7","doi-asserted-by":"crossref","unstructured":"Riely GJ, Wood DE, Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(4):249\u2013274.","DOI":"10.6004\/jnccn.2204.0023"},{"key":"158_CR8","doi-asserted-by":"crossref","unstructured":"Sim EH, Yang IA, Wood-Baker R, et al. Gefitinib for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2018;1(1):CD006847.","DOI":"10.1002\/14651858.CD006847.pub2"},{"key":"158_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2024.122521","volume":"344","author":"H Guo","year":"2024","unstructured":"Guo H, Wang H, Gao M, et al. Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy. Carbohydr Polym. 2024;344:122521.","journal-title":"Carbohydr Polym."},{"issue":"16","key":"158_CR10","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","volume":"29","author":"SM Lim","year":"2023","unstructured":"Lim SM, Fujino T, Kim C, et al. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023;29(16):3004\u20133016.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"158_CR11","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-23-2951","volume":"30","author":"EJ Lee","year":"2024","unstructured":"Lee EJ, Oh SY, Lee YW, et al. Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Clin Cancer Res. 2024;30(8):1582\u20131594.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"158_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41420-021-00744-1","volume":"7","author":"C Xu","year":"2021","unstructured":"Xu C, Zhang L, Wang D, et al. Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer. Cell Death Discov. 2021;7(1):353.","journal-title":"Cell Death Discov."},{"issue":"11","key":"158_CR13","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1016\/j.apsb.2022.08.022","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Ouyang Z, Du H, et al. New opportunities and challenges of natural products research: When target identification meets single-cell multiomics. Acta Pharm Sin B. 2022;12(11):4011\u20134039.","journal-title":"Acta Pharm Sin B."},{"issue":"Pt 2","key":"158_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117270","volume":"319","author":"H Jin","year":"2024","unstructured":"Jin H, Liu C, Liu X, et al. Huaier suppresses cisplatin resistance in non-small cell lung cancer by inhibiting the JNK\/JUN\/IL-8 signaling pathway. J Ethnopharmacol. 2024;319(Pt 2):117270.","journal-title":"J Ethnopharmacol."},{"key":"158_CR15","doi-asserted-by":"publisher","first-page":"1336347","DOI":"10.3389\/fphar.2024.1336347","volume":"15","author":"K Xie","year":"2024","unstructured":"Xie K, Ma M, Xu F. Long-term oral administration of Huaier granules improves survival outcomes in hepatocellular carcinoma patients within Milan criteria following microwave ablation: a propensity score matching and stabilized inverse probability weighting analysis. Front Pharmacol. 2024;15:1336347.","journal-title":"Front Pharmacol."},{"issue":"7","key":"158_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/jof9070702","volume":"9","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jia J, Wang Q, et al. Secondary Metabolites from the Cultures of Medicinal Mushroom Vanderbylia robiniophila and Their Tyrosinase Inhibitory Activities. J Fungi (Basel). 2023;9(7):702.","journal-title":"J Fungi (Basel)."},{"key":"158_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.139357","volume":"293","author":"X Li","year":"2025","unstructured":"Li X, Zhang H, Deng Y, et al. Huaier polysaccharides inhibits hepatocellular carcinoma via gut microbiota mediated M2 macrophage polarization. Int J Biol Macromol. 2025;293:139357.","journal-title":"Int J Biol Macromol."},{"issue":"11","key":"158_CR18","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/gutjnl-2018-315983","volume":"67","author":"Q Chen","year":"2018","unstructured":"Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut. 2018;67(11):2006\u20132016.","journal-title":"Gut."},{"key":"158_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114539","volume":"281","author":"Z Wang","year":"2021","unstructured":"Wang Z, Yu XL, Zhang J, et al. Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study. J Ethnopharmacol. 2021;281:114539.","journal-title":"J Ethnopharmacol."},{"key":"158_CR20","doi-asserted-by":"publisher","first-page":"1163304","DOI":"10.3389\/fphar.2023.1163304","volume":"14","author":"K Shi","year":"2023","unstructured":"Shi K, Bi Y, Zeng X, et al. Effects of adjuvant huaier granule therapy on survival rate of patients with hepatocellular carcinoma. Front Pharmacol. 2023;14:1163304.","journal-title":"Front Pharmacol."},{"issue":"1","key":"158_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/CM9.0000000000002966","volume":"138","author":"Q Guo","year":"2025","unstructured":"Guo Q, Peng Y, Zhang G, et al. Effect of Huaier granule on prognosis of breast cancer: A single-center propensity score matching retrospective study. Chin Med J (Engl). 2025;138(1):93\u201398.","journal-title":"Chin Med J (Engl)."},{"issue":"5","key":"158_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s12094-018-1959-4","volume":"21","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Wang X, Chen T. Efficacy of Huaier granule in patients with breast cancer. Clin Transl Oncol. 2019;21(5):588\u2013595.","journal-title":"Clin Transl Oncol."},{"key":"158_CR23","doi-asserted-by":"publisher","first-page":"2403595","DOI":"10.1155\/2020\/2403595","volume":"2020","author":"J Qi","year":"2020","unstructured":"Qi J, Xie FJ, Liu S, et al. Huaier Granule Combined with Tegafur Gimeracil Oteracil Potassium Promotes Stage IIb Gastric Cancer Prognosis and Induces Gastric Cancer Cell Apoptosis by Regulating Livin. Biomed Res Int. 2020;2020:2403595.","journal-title":"Biomed Res Int."},{"issue":"4","key":"158_CR24","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3892\/ol.2015.2906","volume":"9","author":"Y Cui","year":"2015","unstructured":"Cui Y, Meng H, Liu W, et al. Huaier aqueous extract induces apoptosis of human fibrosarcoma HT1080 cells through the mitochondrial pathway. Oncol Lett. 2015;9(4):1590\u20131596.","journal-title":"Oncol Lett."},{"issue":"6","key":"158_CR25","first-page":"3055","volume":"39","author":"A Yang","year":"2018","unstructured":"Yang A, Zhao Y, Wang Y, et al. Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy. Oncol Rep. 2018;39(6):3055\u20133063.","journal-title":"Oncol Rep."},{"issue":"18","key":"158_CR26","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.7150\/jca.20380","volume":"8","author":"Z Xu","year":"2017","unstructured":"Xu Z, Zheng G, Wang Y, et al. Aqueous Huaier Extract Suppresses Gastric Cancer Metastasis and Epithelial to Mesenchymal Transition by Targeting Twist. J Cancer. 2017;8(18):3876\u20133886.","journal-title":"J Cancer."},{"issue":"3","key":"158_CR27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3892\/ijo.2015.3094","volume":"47","author":"L Yan","year":"2015","unstructured":"Yan L, Liu X, Yin A, et al. Huaier aqueous extract inhibits cervical cancer cell proliferation via JNK\/p38 pathway. Int J Oncol. 2015;47(3):1054\u20131060.","journal-title":"Int J Oncol."},{"key":"158_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jep.2016.03.069","volume":"186","author":"Z Hu","year":"2016","unstructured":"Hu Z, Yang A, Fan H, et al. Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling. J Ethnopharmacol. 2016;186:143\u2013150.","journal-title":"J Ethnopharmacol."},{"key":"158_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.615568","volume":"11","author":"Z Liu","year":"2021","unstructured":"Liu Z, Liu C, Yan K, et al. Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR\/AR-V7 Pathway. Front Oncol. 2021;11:615568.","journal-title":"Front Oncol."},{"issue":"1","key":"158_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12906-019-2614-5","volume":"19","author":"Z Fu","year":"2019","unstructured":"Fu Z, Ma K, Dong B, et al. The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells. BMC Complement Altern Med. 2019;19(1):203.","journal-title":"BMC Complement Altern Med."},{"issue":"6","key":"158_CR31","first-page":"3455","volume":"38","author":"L Yang","year":"2017","unstructured":"Yang L, Song Z, Wang X, et al. Huaier extract enhances the treatment efficacy of paclitaxel in breast cancer cells via the NF-kappaB\/IkappaBalpha pathway. Oncol Rep. 2017;38(6):3455\u20133464.","journal-title":"Oncol Rep."},{"key":"158_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155656","volume":"129","author":"Q Wang","year":"2024","unstructured":"Wang Q, Gong M, Liu R, et al. Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1. Phytomedicine. 2024;129:155656.","journal-title":"Phytomedicine."},{"key":"158_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109071","volume":"117","author":"P Qu","year":"2019","unstructured":"Qu P, Han J, Qiu Y, et al. Huaier extract enhances the treatment efficacy of imatinib in Ik6+ Ph+ acute lymphoblastic leukemia. Biomed Pharmacother. 2019;117:109071.","journal-title":"Biomed Pharmacother."},{"issue":"3B","key":"158_CR34","first-page":"30","volume":"35","author":"JY Xu","year":"2014","unstructured":"Xu JY, Li JX, Zhao ZL, et al. On huaier particles combined gefitinib in advanced lung adenocarcinoma. Med Philos (Chinese). 2014;35(3B):30\u201332.","journal-title":"Med Philos (Chinese)."},{"key":"158_CR35","doi-asserted-by":"crossref","unstructured":"Lv F, Li X, Wang Y. An extraction from Trametes robiniophila Murr. (Huaier) inhibits non-small cell lung cancer proliferation via targeting to epidermal growth factor receptor. Bioengineered. 2022;13(4):10931\u201310943.","DOI":"10.1080\/21655979.2022.2066757"},{"issue":"6724","key":"158_CR36","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.adn7030","volume":"386","author":"AR Brown","year":"2024","unstructured":"Brown AR, Hirschhorn T, Stockwell BR. Ferroptosis-disease perils and therapeutic promise. Science. 2024;386(6724):848\u2013849.","journal-title":"Science."},{"issue":"2","key":"158_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88.","journal-title":"Cell Death Dis."},{"issue":"4","key":"158_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42(4):513\u2013534.","journal-title":"Cancer Cell."},{"issue":"4","key":"158_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao P, Wang W, Wang W, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365\u2013378.e6.","journal-title":"Cancer Cell."},{"issue":"15","key":"158_CR40","first-page":"3700","volume":"45","author":"YY Tian","year":"2020","unstructured":"Tian YY, Yang AL, Chen XN, et al. Effect of Huaier aqueous extract on growth and metastasis of human non-small cell lung cancer NCI-H1299 cells and its underlying mechanisms. Zhongguo Zhong Yao Za Zhi (Chinese). 2020;45(15):3700\u20133706.","journal-title":"Zhongguo Zhong Yao Za Zhi (Chinese)."},{"key":"158_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.960858","volume":"12","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Wang X, Zhang W, et al. Huaier suppresses pancreatic cancer progression via activating cell autophagy induced ferroptosis. Front Oncol. 2022;12:960858.","journal-title":"Front Oncol."},{"key":"158_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110254","volume":"128","author":"C Li","year":"2020","unstructured":"Li C, Wang X, Chen T, et al. Trametes robiniophila Murr in the treatment of breast cancer. Biomed Pharmacother. 2020;128:110254.","journal-title":"Biomed Pharmacother."},{"issue":"1","key":"158_CR43","doi-asserted-by":"publisher","first-page":"8335","DOI":"10.1038\/s41467-025-64035-4","volume":"16","author":"J Zhang","year":"2025","unstructured":"Zhang J, Mao P, Zhou T, et al. Macrophage ferroptosis potentiates GCN2 deficiency induced pulmonary venous arterialization. Nat Commun. 2025;16(1):8335.","journal-title":"Nat Commun."},{"issue":"1","key":"158_CR44","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s42003-023-05272-5","volume":"6","author":"Y Dai","year":"2023","unstructured":"Dai Y, Chen Y, Mo D, et al. Inhibition of ACSL4 ameliorates tubular ferroptotic cell death and protects against fibrotic kidney disease. Commun Biol. 2023;6(1):907.","journal-title":"Commun Biol."},{"issue":"12","key":"158_CR45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol."},{"issue":"D1","key":"158_CR46","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa M, Furumichi M, Sato Y, et al. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 2025;53(D1):D672\u2013D677.","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"158_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res."},{"key":"158_CR48","doi-asserted-by":"crossref","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.","DOI":"10.1093\/bib\/bbab260"},{"key":"158_CR49","doi-asserted-by":"crossref","unstructured":"Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955\u201361.","DOI":"10.1093\/nar\/gks1111"},{"issue":"1","key":"158_CR50","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12859-023-05615-3","volume":"24","author":"C Liao","year":"2023","unstructured":"Liao C, Wang X. TCGAplot: an R package for integrative pan-cancer analysis and visualization of TCGA multi-omics data. BMC Bioinformatics. 2023;24(1):483.","journal-title":"BMC Bioinformatics."},{"issue":"3","key":"158_CR51","volume":"5","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation (Camb). 2024;5(3):100625.","journal-title":"Innovation (Camb)."},{"issue":"2","key":"158_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7150\/ijms.89308","volume":"21","author":"T Wu","year":"2024","unstructured":"Wu T, Liu S, Chen W, et al. Huaier suppresses cell viability, migration and invasion in human non-small cell lung cancer via lncRNA DLEU2\/miR-212-5p\/ELF3 axis. Int J Med Sci. 2024;21(2):319\u2013331.","journal-title":"Int J Med Sci."},{"issue":"1","key":"158_CR53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12931-020-01477-y","volume":"21","author":"C Sun","year":"2020","unstructured":"Sun C, Gao W, Liu J, et al. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir Res. 2020;21(1):210.","journal-title":"Respir Res."},{"key":"158_CR54","first-page":"75","volume":"12","author":"YH Pan","year":"2018","unstructured":"Pan YH, Jiao L, Lin CY, et al. Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway. Biologics. 2018;12:75\u201386.","journal-title":"Biologics."},{"issue":"12","key":"158_CR55","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/j.febslet.2014.04.044","volume":"588","author":"T Wu","year":"2014","unstructured":"Wu T, Chen W, Liu S, et al. Huaier suppresses proliferation and induces apoptosis in human pulmonary cancer cells via upregulation of miR-26b-5p. FEBS Lett. 2014;588(12):2107\u20132114.","journal-title":"FEBS Lett."},{"issue":"7","key":"158_CR56","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1200\/JCO.20.01820","volume":"39","author":"WZ Zhong","year":"2021","unstructured":"Zhong WZ, Wang Q, Mao WM, et al. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2021;39(7):713\u2013722.","journal-title":"J Clin Oncol."},{"issue":"2","key":"158_CR57","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.pccm.2023.04.006","volume":"1","author":"R Han","year":"2023","unstructured":"Han R, Li J, Wang Y, et al. Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial. Chin Med J Pulm Crit Care Med. 2023;1(2):119\u2013124.","journal-title":"Chin Med J Pulm Crit Care Med."},{"issue":"7","key":"158_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167447","volume":"1870","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Qian J, Fu Y, et al. Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer. Biochim Biophys Acta Mol Basis Dis. 2024;1870(7):167447.","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"issue":"10","key":"158_CR59","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/1078-0432.CCR-22-3318","volume":"29","author":"CK Liam","year":"2023","unstructured":"Liam CK, Ahmad AR, Hsia TC, et al. Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clin Cancer Res. 2023;29(10):1879\u20131886.","journal-title":"Clin Cancer Res."},{"issue":"Pt A","key":"158_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116646","volume":"318","author":"Q Tang","year":"2024","unstructured":"Tang Q, Xu M, Long S, et al. FZKA reverses gefitinib resistance by regulating EZH2\/Snail\/EGFR signaling pathway in lung adenocarcinoma. J Ethnopharmacol. 2024;318(Pt A):116646.","journal-title":"J Ethnopharmacol."},{"issue":"1","key":"158_CR61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/13880209.2023.2292266","volume":"62","author":"J Wang","year":"2024","unstructured":"Wang J, He X, Jia Z, et al. Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22\/STAT3\/AKT pathway. Pharm Biol. 2024;62(1):33\u201341.","journal-title":"Pharm Biol."},{"issue":"4","key":"158_CR62","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3892\/ol.2024.14599","volume":"28","author":"W Yao","year":"2024","unstructured":"Yao W, Liu C, Zhang N, et al. Atractyloside inhibits gefitinib\u2011resistant non\u2011small\u2011cell lung cancer cell proliferation. Oncol Lett. 2024;28(4):466.","journal-title":"Oncol Lett."},{"key":"158_CR63","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2021.06.051","volume":"567","author":"J Ni","year":"2021","unstructured":"Ni J, Chen K, Zhang J, et al. Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells. Biochem Biophys Res Commun. 2021;567:154\u2013160.","journal-title":"Biochem Biophys Res Commun."},{"issue":"14","key":"158_CR64","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401\u20132421.","journal-title":"Cell."},{"issue":"7","key":"158_CR65","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.tem.2024.09.003","volume":"36","author":"J Lin","year":"2025","unstructured":"Lin J, Lai Y, Lu F, et al. Targeting ACSLs to modulate ferroptosis and cancer immunity. Trends Endocrinol Metab. 2025;36(7):677\u2013690.","journal-title":"Trends Endocrinol Metab."},{"issue":"1","key":"158_CR66","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13062-021-00294-7","volume":"16","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li S, Li F, et al. High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma. Biol Direct. 2021;16(1):10.","journal-title":"Biol Direct."},{"issue":"3","key":"158_CR67","doi-asserted-by":"publisher","first-page":"140","DOI":"10.36401\/JIPO-22-29","volume":"6","author":"M Alali","year":"2023","unstructured":"Alali M, Saifo M. Optimizing the Treatment for Advanced Non-Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review. J Immunother Precis Oncol. 2023;6(3):140\u2013149.","journal-title":"J Immunother Precis Oncol."},{"issue":"15","key":"158_CR68","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1158\/1078-0432.CCR-23-4035","volume":"30","author":"A Fukuda","year":"2024","unstructured":"Fukuda A, Okuma Y. From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2024;30(15):3128\u20133136.","journal-title":"Clin Cancer Res."}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00158-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-025-00158-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00158-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:03:09Z","timestamp":1772193789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-025-00158-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["158"],"URL":"https:\/\/doi.org\/10.1007\/s11596-025-00158-5","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The experimental animal research protocol was approved by the Animal Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (Approval No. 4174), and all animal experiments were carried out in compliance with the Guide for the Care and Use of Laboratory Animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}